Outcome of COVID-19 infection in multiple sclerosis patients receiving disease-modifying therapies

BACKGROUND: With the spread of COVID-19, treatment of diseases such as multiple sclerosis (MS) should be resumed with caution due to the disease-modifying therapies (DMTs) used in this subset of patients and the immunoregulatory effects of these drugs. We aim to assess the outcome of COVID-19 infect...

Descripción completa

Detalles Bibliográficos
Autores principales: Etemadifar, Masoud, Sami, Ramin, Salari, Mehri, Sedaghat, Nahad, Sigari, Amirhossein Akhavan, Aghababaei, Ali, Najafi, Mohammadreza, Tehrani, Donya Sheibani
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548892/
https://www.ncbi.nlm.nih.gov/pubmed/34760002
http://dx.doi.org/10.4103/jrms.JRMS_1047_20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548892/
https://www.ncbi.nlm.nih.gov/pubmed/34760002
http://dx.doi.org/10.4103/jrms.JRMS_1047_20

Ejemplares similares